Evotec (NASDAQ:EVO) Stock Price Up 2.7% – Should You Buy?

Evotec AG (NASDAQ:EVO)’s share price shot up 2.7% on Wednesday . The stock traded as high as $2.76 and last traded at $2.69. 21,810 shares traded hands during trading, a decline of 34% from the average session volume of 32,857 shares. The stock had previously closed at $2.62.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Evotec from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright initiated coverage on Evotec in a research report on Wednesday, April 15th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Weiss Ratings raised Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Evotec Stock Performance

The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.60 and a current ratio of 1.68. The business’s 50 day moving average is $2.93 and its two-hundred day moving average is $3.06.

Evotec (NASDAQ:EVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%.The business had revenue of $297.02 million during the quarter. As a group, equities analysts expect that Evotec AG will post -0.63 earnings per share for the current year.

Institutional Trading of Evotec

Several institutional investors have recently made changes to their positions in EVO. Apollon Wealth Management LLC bought a new stake in Evotec during the 1st quarter valued at approximately $28,000. Marshall Wace LLP bought a new position in Evotec in the 4th quarter worth approximately $40,000. SmartHarvest Portfolios LLC purchased a new stake in Evotec during the 1st quarter valued at approximately $44,000. BNP Paribas Financial Markets grew its holdings in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after buying an additional 4,600 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares in the last quarter. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.